US-based clinical-stage immuno-oncology company TapImmune has signed an agreement to merge with Marker Therapeutics.
The merger has been unanimously approved by the board of directors of both companies.
Go deeper with GlobalData
The existing shareholders of Marker Therapeutics will acquire newly issued shares and warrants of TapImmune’s common stock equal to the existing outstanding common stock of the latter.
TapImmune currently has 10.7 million outstanding shares and seven million warrants.
The stockholders of both companies will each own half of the combined company, upon completion of the transaction.
Peter Hoang, the CEO of TapImmune, will act as the president and CEO of the combined company, while the CEO of Marker Therapeutics, John Wilson, and co-founder Juan Vera will join the combined company’s board of directors.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe board of directors of the combined company will have a total of eight members, including three members each from TapImmune and Marker Therapeutics, and two from the investor syndicate.
The merger transaction will create a highly differentiated company in the immuno-oncology field.
TapImmune has appointed Nomura Securities International as financial adviser and Seyfarth Shaw as legal adviser for the transaction, while Marker Therapeutics has appointed Winthrop & Weinstine, PA as legal adviser.
CalibreScientific has completed the acquisition of BIOZOL Diagnostica Vertrieb.
Based in the US, the acquirer company is a provider of diversified services for the healthcare life sciences industry, while the target company, based in Germany, is involved in the distribution of life science products including antibodies, proteins, Enzyme Linked Immunosorbent Assays (ELISAs), detection kits, biochemicals, reagents and diagnostics kits.
Medicover Holding has agreed to purchase a majority share in Spitalul Clinic Pelican for €23m ($27.51m).
Medicover will acquire 80% share and clinical business of Spitalul Pelican, as part of the transaction.
The acquisition is subject to approval by the Romanian Competition Council.
Based in Luxembourg, Medicover Holding is involved in the provision of healthcare and diagnostic services, while Spitalul Pelican is a healthcare services provider based in Romania.
